Please Wait.....

Report

Global Self-injections Market

Market Report I 2024-09-01 I 553 Pages I Data Bridge Market Research

Global self-injection market is expected to reach USD 97.36 billion by 2031 from USD 46.18 billion in 2023, growing with a CAGR of 10.0% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Self-injections Market, By Product Type (Self-Injection Devices and Self-Injection Formulation), Dosage Form (Single Dose and Multi-Dose), Route of Administration (Subcutaneous, Intra muscular, and Others), Application (Autoimmune Diseases, Pain Management, Emergency Drugs, Oncology, Hormonal Disorders, and Others), Age Group (Adult, Geriatric, and Pediatric), Gender (Male and Female), Distribution Channel (Direct Tender, Hospital Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Philippines, New Zealand, Taiwan, Vietnam, Rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Denmark, Sweden, Norway, Poland, Finland, Rest of Europe, South Africa, U.A.E., Egypt, Saudi Arabia, Israel, Kuwait, Oman, Qatar, Bahrain, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America) - Industry Trends and Forecast to 2031
Overview of Global Self-Injections Market Dynamics:
Driver
- Rising prevalence of chronic disease
Restraint
- High cost of self injectors
Opportunity
- Government initiatives to self-injections
Market Players:
The key market players operating in the global self-injection market are listed below:
- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- Biogen
- Amgen Inc.
- Sanofi
- AbbVie Inc.
- YPSOMED
- BD
- AstraZeneca
- AptarGroup, Inc.
- Bayer AG
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmBH
- Credence Medsystems, Inc.
- Dali Medical Devices
- Enable Injections
- E3D Elcam Drug Delivery Devices
- F. Hoffmann-La Roche Ltd
- GSK plc
- Gerresheimer AG
- Haselmeier
- Ipsen Biopharmaceuticals, Inc.
- Lilly
- Midas Pharma GmBH
- Merck & Co., Inc.
- Novartis AG
- Nemera
- OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
- Owen Mumford
- Pfizer Inc.
- Philips-Medisize
- PharmaJet
- PenJet
- Recipharm AB
- SCHOTT PHARMA
- SHL Medical AG
- Societe Industrielle de Sonceboz SA
- Terumo Corporation
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- UCB Pharma
- West Pharmaceutical Service

1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF GLOBAL SELF-INJECTIONS MARKET 52
1.4 MARKETS COVERED 55
2 MARKET SEGMENTATION 58
2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 THERAPEUTICS LIFELINE CURVE 64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 VENDOR SHARE ANALYSIS 67
2.11 MARKET APPLICATION COVERAGE GRID 68
2.12 SECONDARY SOURCES 69
2.13 ASSUMPTIONS 69
3 EXECUTIVE SUMMARY 70
4 PREMIUM INSIGHT 77
4.1 PORTER'S FIVE FORCES 79
4.2 PESTEL ANALYSIS 80
4.3 CUSTOMIZATIONS 81
5 GLOBAL SELF-INJECTIONS MARKET: REGULATIONS 86
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 86
5.1.1 AUSTRALIA 86
5.1.2 CHINA 88
5.1.3 INDIA 90
5.2 REGULATORY SUBMISSIONS 91
5.2.1 PRE-SUBMISSION ACTIVITIES 91
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION 92
5.3 CLINICAL EVALUATION 92
5.4 REGULATORY SUBMISSION PREPARATION 92
5.5 SUBMISSION TO REGULATORY AUTHORITY 92
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY 92
5.7 APPROVAL AND MARKET AUTHORIZATION 93
5.8 POST-MARKET SURVEILLANCE 93
5.9 RENEWAL AND COMPLIANCE 93
5.10 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD) 93
5.11 ADOPTION OF GLOBAL STANDARDS (ISO AND IEC) 94
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE 94
5.13 CLINICAL DATA HARMONIZATION 94
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT 94
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION 94
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS) 94
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES 95
5.18 NORTH AMERICA REGULATORY SCENARIO 95
5.19 MEDICAL DEVICE CLASSIFICATION 97
5.20 REGULATORY SUBMISSIONS 100
5.21 EUROPE REGULATORY SCENARIO 102
5.22 REGULATORY SUBMISSIONS 104
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 106
5.24 SOUTH AMERICA REGULATORY SCENARIO 113
5.25 INTERNATIONAL HARMONIZATION 117
6 MARKET OVERVIEW 121
6.1 DRIVERS 123
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE 123
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS 123
6.1.3 INCREASE IN PATIENT AUTONOMY 124
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS 124
6.2 RESTRAINTS 126
6.2.1 HIGH COST OF SELF INJECTORS 126
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES 127
6.3 OPPORTUNITIES 128
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS 128
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION 129
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE 130
6.4 CHALLENGES 131
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES 131
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS 131
7 GLOBAL SELF-INJECTIONS MARKET, BY PRODUCT TYPE 133
7.1 OVERVIEW 134
7.2 SELF-INJECTION DEVICES 137
7.3 SELF-INJECTION FORMULATION 139
8 GLOBAL SELF-INJECTIONS MARKET, BY DOSAGE FORM 140
8.1 OVERVIEW 141
8.2 SINGLE DOSE 144
8.3 MULTI-DOSE 144
9 GLOBAL SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION 145
9.1 OVERVIEW 146
9.2 SUBCUTANEOUS 149
9.3 INTRA MUSCULAR 149
9.4 OTHERS 150
10 GLOBAL SELF-INJECTIONS MARKET, BY APPLICATION 151
10.1 OVERVIEW 152
10.2 AUTOIMMUNE DISEASES 155
10.3 PAIN MANAGEMENT 156
10.4 EMERGENCY DRUGS 156
10.5 ONCOLOGY 157
10.6 HORMONAL DISORDERS 157
10.7 OTHERS 158
11 GLOBAL SELF-INJECTIONS MARKET, BY AGE GROUP 159
11.1 OVERVIEW 160
11.2 ADULT 163
11.3 GERIATRIC 163
11.4 PEDIATRIC 164
12 GLOBAL SELF-INJECTIONS MARKET, BY GENDER 165
12.1 OVERVIEW 166
12.2 MALE 169
12.3 FEMALE 169
13 GLOBAL SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL 170
13.1 OVERVIEW 171
13.2 DIRECT TENDER 174
13.3 HOSPITAL PHARMACY 174
13.4 ONLINE PHARMACY 175
13.5 OTHERS 175
14 GLOBAL SELF-INJECTIONS MARKET, BY REGION 176
14.1 OVERVIEW 177
14.2 GLOBAL 178
14.3 NORTH AMERICA 181
14.4 EUROPE 205
14.5 ASIA-PACIFIC 302
14.6 SOUTH AMERICA 377
14.7 MIDDLE EAST AND AFRICA 394
15 GLOBAL SELF-INJECTIONS MARKET: COMPANY LANDSCAPE 449
15.1 COMPANY SHARE ANALYSIS: GLOBAL 449
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 450
15.3 COMPANY SHARE ANALYSIS: EUROPE 451
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 452
16 SWOT ANALYSIS 453
17 COMPANY PROFILES 454
17.1 NOVO NORDISK 454
17.1.1 COMPANY SNAPSHOT 454
17.1.2 REVENUE 455
17.1.3 COMPANY SHARE ANALYSIS 455
17.1.4 PRODUCT PORTFOLIO 456
17.1.5 RECENT DEVELOPMENT 457
17.2 JOHNSON & JOHNSON SERVICES, INC. 458
17.2.1 COMPANY SNAPSHOT 458
17.2.2 REVENUE ANALYSIS 458
17.2.3 COMPANY SHARE ANALYSIS 459
17.2.4 PRODUCT PORTFOLIO 459
17.2.5 RECENT DEVELOPMENT 459
17.3 BIOGEN 461
17.3.1 COMPANY SNAPSHOT 461
17.3.2 REVENUE ANALYSIS 461
17.3.3 PRODUCT PORTFOLIO 462
17.3.4 RECENT DEVELOPMENT 463
17.4 AMGEN INC. 464
17.4.1 COMPANY SNAPSHOT 464
17.4.2 REVENUE ANALYSIS 464
17.4.3 COMPANY SHARE ANALYSIS 465
17.4.4 PRODUCT PORTFOLIO 465
17.4.5 RECENT DEVELOPMENT 465
17.5 SANOFI 466
17.5.1 COMPANY SNAPSHOT 466
17.5.2 REVENUE ANALYSIS 466
17.5.3 COMPANY SHARE ANALYSIS 467
17.5.4 PRODUCT PORTFOLIO 467
17.5.5 RECENT DEVELOPMENT 468
17.6 ABBVIE INC. 469
17.6.1 COMPANY SNAPSHOT 469
17.6.2 REVENUE ANALYSIS 469
17.6.3 COMPANY SHARE ANALYSIS 470
17.6.4 PRODUCT PORTFOLIO 470
17.6.5 RECENT DEVELOPMENT 470
17.7 YPSOMED 471
17.7.1 COMPANY SNAPSHOT 471
17.7.2 REVENUE ANALYSIS 471
17.7.3 PRODUCT PORTFOLIO 472
17.7.4 RECENT DEVELOPMENT 472
17.8 BD 473
17.8.1 COMPANY SNAPSHOT 473
17.8.2 REVENUE ANALYSIS 473
17.8.3 PRODUCT PORTFOLIO 474
17.8.4 RECENT DEVELOPMENT 474
17.9 ASTRAZENECA 475
17.9.1 COMPANY SNAPSHOT 475
17.9.2 REVENUE ANALYSIS 475
17.9.3 PRODUCT PORTFOLIO 476
17.9.4 RECENT DEVELOPMENTS 476
17.10 APTARGROUP, INC. 477
17.10.1 COMPANY SNAPSHOT 477
17.10.2 REVENUE ANALYSIS 477
17.10.3 PRODUCT PORTFOLIO 478
17.10.4 RECENT DEVELOPMENTS 478
17.11 BAYER 479
17.11.1 COMPANY SNAPSHOT 479
17.11.2 REVENUE 479
17.11.3 PRODUCT PORTFOLIO 480
17.11.4 RECENT DEVELOPMENT 480
17.12 BAUSCH HEALTH COMPANIES INC. 481
17.12.1 COMPANY SNAPSHOT 481
17.12.2 REVENUE ANALYSIS 481
17.12.3 PRODUCT PORTFOLIO 482
17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 483
17.13.1 COMPANY SNAPSHOT 483
17.13.2 REVENUE ANALYSIS 484
17.13.3 PRODUCT PORTFOLIO 484
17.13.4 RECENT DEVELOPMENTS 485
17.14 CREDENCE MEDSYSTEMS, INC. 486
17.14.1 COMPANY SNAPSHOT 486
17.14.2 PRODUCT PORTFOLIO 486
17.14.3 RECENT DEVELOPMENT 488
17.15 DALI MEDICAL DEVICES 489
17.15.1 COMPANY SN.APSHOT 489
17.15.2 PRODUCT PORTFOLIO 489
17.15.3 RECENT DEVELOPMENT 492
17.16 ENABLE INJECTIONS 493
17.16.1 COMPANY SNAPSHOT 493
17.16.2 PRODUCT PORTFOLIO 493
17.16.3 RECENT DEVELOPMENTS 494
17.17 E3D ELCAM DRUG DELIVERY DEVICES 496
17.17.1 COMPANY SNAPSHOT 496
17.17.2 PRODUCT PORTFOLIO 496
17.17.3 RECENT DEVELOPMENT 498
17.18 F. HOFFMANN-LA ROCHE LTD 499
17.18.1 COMPANY SNAPSHOT 499
17.18.2 REVENUE ANALYSIS 499
17.18.3 PRODUCT PORTFOLIO 500
17.18.4 RECENT DEVELOPMENT 500
17.19 GSK PLC 501
17.19.1 COMPANY SNAPSHOT 501
17.19.2 REVENUE ANALYSIS 501
17.19.3 PRODUCT PORTFOLIO 502
17.19.4 RECENT DEVELOPMENTS 502
17.20 GERRESHEIMER AG 503
17.20.1 COMPANY SNAPSHOT 503
17.20.2 REVENUE ANALYSIS 503
17.20.3 PRODUCT PORTFOLIO 504
17.20.4 RECENT DEVELOPMENTS 505
17.21 HASELMEIER 506
17.21.1 COMPANY SNAPSHOT 506
17.21.2 PRODUCT PORTFOLIO 506
17.21.3 RECENT DEVELOPMENT 508
17.22 IPSEN BIOPHARMACEUTICALS, INC. 509
17.22.1 COMPANY SNAPSHOT 509
17.22.2 REVENUE ANALYSIS 510
17.22.3 PRODUCT PORTFOLIO 510
17.22.4 RECENT DEVELOPMENT 510
17.23 LILLY 511
17.23.1 COMPANY SNAPSHOT 511
17.23.2 REVENUE ANALYSIS 511
17.23.3 PRODUCT PORTFOLIO 512
17.23.4 RECENT DEVELOPMENT 512
17.24 MIDAS PHARMA GMBH 513
17.24.1 COMPANY SNAPSHOT 513
17.24.2 PRODUCT PORTFOLIO 513
17.24.3 RECENT DEVELOPMENT 513
17.25 MERCK & CO., INC., 514
17.25.1 COMPANY SNAPSHOT 514
17.25.2 REVENUE ANALYSIS 514
17.25.3 PRODUCT PORTFOLIO 515
17.25.4 RECENT DEVELOPMENT 515
17.26 NOVARTIS AG 516
17.26.1 COMPANY SNAPSHOT 516
17.26.2 REVENUE ANALYSIS 517
17.26.3 PRODUCT PORTFOLIO 517
17.26.4 RECENT DEVELOPMENTS 517
17.27 NEMERA 519
17.27.1 COMPANY SNAPSHOT 519
17.27.2 PRODUCT PORTFOLIO 519
17.27.3 RECENT DEVELOPMENT 521
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED) 522
17.28.1 COMPANY SNAPSHOT 522
17.28.2 PRODUCT PORTFOLIO 522
17.28.3 RECENT DEVELOPMENT 523
17.29 OWEN MUMFORD 524
17.29.1 COMPANY SNAPSHOT 524
17.29.2 PRODUCT PORTFOLIO 524
17.29.3 RECENT DEVELOPMENT 524
17.30 PFIZER INC. 525
17.30.1 COMPANY SNAPSHOT 525
17.30.2 REVENUE ANALYSIS 525
17.30.3 PRODUCT PORTFOLIO 526
17.30.4 RECENT DEVELOPMENT 526
17.30.5 RECENT DEVELOPMENT 526
17.31 PHILIP MEDSIZE 527
17.31.1 COMPANY SNAPSHOT 527
17.31.2 PRODUCT PORTFOLIO 527
17.31.3 RECENT DEVELOPMENTS 528
17.32 PHARMAJET. 529
17.32.1 COMPANY SNAPSHOT 529
17.32.2 PRODUCT PORTFOLIO 529
17.32.3 RECENT DEVELOPMENT 529
17.33 PENJET 530
17.33.1 COMPANY SNAPSHOT 530
17.33.2 1.1.4 PRODUCT PORTFOLIO 530
17.33.3 RECENT DEVELOPMENT 530
17.34 RECIPHARM AB 531
17.34.1 COMPANY SNAPSHOT 531
17.34.2 PRODUCT PORTFOLIO 531
17.34.3 RECENT DEVELOPMENTS 532
17.35 SCHOTT PHARMA 533
17.35.1 COMPANY SNAPSHOT 533
17.35.2 PRODUCT PORTFOLIO 533
17.35.3 RECENT DEVELOPMENTS 534
17.36 SHL MEDICAL AG 535
17.36.1 COMPANY SNAPSHOT 535
17.36.2 PRODUCT PORTFOLIO 535
17.36.3 RECENT DEVELOPMENT 536
17.37 SOCIETE INDUSTRIELLE DE SONCEBOZ SA 537
17.37.1 COMPANY SNAPSHOT 537
17.37.2 PRODUCT PORTFOLIO 537
17.37.3 RECENT DEVELOPMENT 537
17.38 TERUMO CORPORATION 538
17.38.1 COMPANY SNAPSHOT 538
17.38.2 REVENUE ANALYSIS 538
17.38.3 PRODUCT PORTFOLIO 539
17.38.4 RECENT DEVELOPMENT 539
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED 541
17.39.1 COMPANY SNAPSHOT 541
17.39.2 REVENUE ANALYSIS 542
17.39.3 PRODUCT PORTFOLIO 542
17.39.4 RECENT DEVELOPMENT 542
17.40 TEVA PHARMACEUTICALS 543
17.40.1 COMPANY SNAPSHOT 543
17.40.2 REVENUE 543
17.40.3 PRODUCT PORTFOLIO 544
17.40.4 RECENT DEVELOPMENT 544
17.41 UCB PHARMA 545
17.41.1 COMPANY SNAPSHOT 545
17.41.2 REVENUE 545
17.41.3 PRODUCT PORTFOLIO 546
17.41.4 RECENT DEVELOPMENT 546
17.42 WEST PHARMACEUTICAL SERVICES 547
17.42.1 COMPANY SNAPSHOT 547
17.42.2 REVENUE ANALYSIS 547
17.42.3 PRODUCT PORTFOLIO 548
17.42.4 RECENT DEVELOPMENTS 549
18 QUESTIONNAIRE 550
19 RELATED REPORTS 553

17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED) 522
17.28.1 COMPANY SNAPSHOT 522
17.28.2 PRODUCT PORTFOLIO 522
17.28.3 RECENT DEVELOPMENT 523
17.29 OWEN MUMFORD 524
17.29.1 COMPANY SNAPSHOT 524
17.29.2 PRODUCT PORTFOLIO 524
17.29.3 RECENT DEVELOPMENT 524
17.30 PFIZER INC. 525
17.30.1 COMPANY SNAPSHOT 525
17.30.2 REVENUE ANALYSIS 525
17.30.3 PRODUCT PORTFOLIO 526
17.30.4 RECENT DEVELOPMENT 526
17.30.5 RECENT DEVELOPMENT 526
17.31 PHILIP MEDSIZE 527
17.31.1 COMPANY SNAPSHOT 527
17.31.2 PRODUCT PORTFOLIO 527
17.31.3 RECENT DEVELOPMENTS 528
17.32 PHARMAJET. 529
17.32.1 COMPANY SNAPSHOT 529
17.32.2 PRODUCT PORTFOLIO 529
17.32.3 RECENT DEVELOPMENT 529
17.33 PENJET 530
17.33.1 COMPANY SNAPSHOT 530
17.33.2 1.1.4 PRODUCT PORTFOLIO 530
17.33.3 RECENT DEVELOPMENT 530
17.34 RECIPHARM AB 531
17.34.1 COMPANY SNAPSHOT 531
17.34.2 PRODUCT PORTFOLIO 531
17.34.3 RECENT DEVELOPMENTS 532
17.35 SCHOTT PHARMA 533
17.35.1 COMPANY SNAPSHOT 533
17.35.2 PRODUCT PORTFOLIO 533
17.35.3 RECENT DEVELOPMENTS 534
17.36 SHL MEDICAL AG 535
17.36.1 COMPANY SNAPSHOT 535
17.36.2 PRODUCT PORTFOLIO 535
17.36.3 RECENT DEVELOPMENT 536
17.37 SOCIETE INDUSTRIELLE DE SONCEBOZ SA 537
17.37.1 COMPANY SNAPSHOT 537
17.37.2 PRODUCT PORTFOLIO 537
17.37.3 RECENT DEVELOPMENT 537
17.38 TERUMO CORPORATION 538
17.38.1 COMPANY SNAPSHOT 538
17.38.2 REVENUE ANALYSIS 538
17.38.3 PRODUCT PORTFOLIO 539
17.38.4 RECENT DEVELOPMENT 539
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED 541
17.39.1 COMPANY SNAPSHOT 541
17.39.2 REVENUE ANALYSIS 542
17.39.3 PRODUCT PORTFOLIO 542
17.39.4 RECENT DEVELOPMENT 542
17.40 TEVA PHARMACEUTICALS 543
17.40.1 COMPANY SNAPSHOT 543
17.40.2 REVENUE 543
17.40.3 PRODUCT PORTFOLIO 544
17.40.4 RECENT DEVELOPMENT 544
17.41 UCB PHARMA 545
17.41.1 COMPANY SNAPSHOT 545
17.41.2 REVENUE 545
17.41.3 PRODUCT PORTFOLIO 546
17.41.4 RECENT DEVELOPMENT 546
17.42 WEST PHARMACEUTICAL SERVICES 547
17.42.1 COMPANY SNAPSHOT 547
17.42.2 REVENUE ANALYSIS 547
17.42.3 PRODUCT PORTFOLIO 548
17.42.4 RECENT DEVELOPMENTS 549
18 QUESTIONNAIRE 550
19 RELATED REPORTS 553
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.